EP Patent

EP4512475A2 — Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections

Assigned to Gilead Sciences Inc · Expires 2025-02-26 · 1y expired

What this patent protects

The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.

USPTO Abstract

The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.

Drugs covered by this patent

Patent Metadata

Patent number
EP4512475A2
Jurisdiction
EP
Classification
—
Expires
2025-02-26
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.